{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:54:49Z","timestamp":1791111289396,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T00:00:00Z","timestamp":1174348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2007,10,2]]},"DOI":"10.1007\/s00280-007-0451-6","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T10:10:26Z","timestamp":1174299026000},"page":"89-96","source":"Crossref","is-referenced-by-count":56,"title":["Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice"],"prefix":"10.1007","volume":"61","author":[{"given":"Roni","family":"Haklai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Elad-Sfadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Egozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoel","family":"Kloog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,3,20]]},"reference":[{"key":"451_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0925-4439(97)00077-X","volume":"1406","author":"Z Aharonson","year":"1998","unstructured":"Aharonson Z, Gana Weisz M, Varsano T, Haklai R, Marciano D, Kloog Y (1998) Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta 1406:40\u201350","journal-title":"Biochim Biophys Acta"},{"key":"451_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2004.04.004","volume":"14","author":"Y Kloog","year":"2004","unstructured":"Kloog Y, Cox AD (2004) Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol 14:253\u201361","journal-title":"Semin Cancer Biol"},{"key":"451_CR3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1357-4310(00)01789-5","volume":"6","author":"Y Kloog","year":"2000","unstructured":"Kloog Y, Cox AD (2000) RAS inhibitors: potential for cancer therapeutics. Mol Med Today 6:398\u2013402","journal-title":"Mol Med Today"},{"key":"451_CR4","doi-asserted-by":"crossref","first-page":"34922","DOI":"10.1074\/jbc.M312697200","volume":"279","author":"G Elad-Sfadia","year":"2004","unstructured":"Elad-Sfadia G, Haklai R, Balan E, Kloog Y (2004) Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 279:34922\u201330","journal-title":"J Biol Chem"},{"key":"451_CR5","doi-asserted-by":"crossref","first-page":"37169","DOI":"10.1074\/jbc.M205698200","volume":"277","author":"G Elad-Sfadia","year":"2002","unstructured":"Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y (2002) Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 277:37169\u201375","journal-title":"J Biol Chem"},{"key":"451_CR6","doi-asserted-by":"crossref","first-page":"7486","DOI":"10.1038\/sj.onc.1204950","volume":"20","author":"A Paz","year":"2001","unstructured":"Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y (2001) Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20:7486\u201393","journal-title":"Oncogene"},{"key":"451_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drup.2005.11.002","volume":"8","author":"R Blum","year":"2005","unstructured":"Blum R, Kloog Y (2005) Tailoring Ras-pathway\u2013inhibitor combinations for cancer therapy. Drug Resist Updat 8:369\u201380","journal-title":"Drug Resist Updat"},{"key":"451_CR8","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1158\/1078-0432.CCR-04-2071","volume":"11","author":"S Yaari","year":"2005","unstructured":"Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y (2005) Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 11:4321\u201330","journal-title":"Clin Cancer Res"},{"key":"451_CR9","doi-asserted-by":"crossref","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","volume":"270","author":"M Marom","year":"1995","unstructured":"Marom M, Haklai R, Ben Baruch G, Marciano D, Egozi Y, Kloog Y (1995) Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270:22263\u201370","journal-title":"J Biol Chem"},{"key":"451_CR10","doi-asserted-by":"crossref","first-page":"14019","DOI":"10.1073\/pnas.96.24.14019","volume":"96","author":"B Jansen","year":"1999","unstructured":"Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, Pehamberger H, Gana-Weisz M, Ben-David E, Kloog Y, Wolff K (1999) Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A 96:14019\u201324","journal-title":"Proc Natl Acad Sci U S A"},{"key":"451_CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","volume":"1452","author":"G Elad","year":"1999","unstructured":"Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y (1999) Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452:228\u201342","journal-title":"Biochim Biophys Acta"},{"key":"451_CR12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0092-8674(00)00115-X","volume":"103","author":"D Bar-Sagi","year":"2000","unstructured":"Bar-Sagi D, Hall A (2000) Ras and Rho GTPases: a family reunion. Cell 103:227\u201338","journal-title":"Cell"},{"key":"451_CR13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/366643a0","volume":"366","author":"MS Boguski","year":"1993","unstructured":"Boguski MS, McCormick F (1993) Proteins regulating Ras and its relatives. Nature 366:643\u201354","journal-title":"Nature"},{"key":"451_CR14","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682\u20139","journal-title":"Cancer Res"},{"key":"451_CR15","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1517\/13543784.8.12.2121","volume":"8","author":"Y Kloog","year":"1999","unstructured":"Kloog Y, Cox AD, Sinensky M (1999) Concepts in Ras-directed therapy. Expert Opin Investig Drugs 8:2121\u201340","journal-title":"Expert Opin Investig Drugs"},{"key":"451_CR16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0955-0674(03)00016-4","volume":"15","author":"TG Bivona","year":"2003","unstructured":"Bivona TG, Philips MR (2003) Ras pathway signaling on endomembranes. Curr Opin Cell Biol 15:136\u201342","journal-title":"Curr Opin Cell Biol"},{"key":"451_CR17","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1074\/jbc.M210202200","volume":"278","author":"GV Denis","year":"2003","unstructured":"Denis GV, Yu Q, Ma P, Deeds L, Faller DV, Chen CY (2003) Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem 278:5775\u201385","journal-title":"J Biol Chem"},{"key":"451_CR18","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1074\/jbc.274.3.1606","volume":"274","author":"H Niv","year":"1999","unstructured":"Niv H, Gutman O, Henis YI, Kloog Y (1999) Membrane interactions of a constitutively active GFP-K-Ras 4B and their role in signaling: Evidence from lateral mobility studies. J Biol Chem 274:1606\u201313","journal-title":"J Biol Chem"},{"key":"451_CR19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/bi972032d","volume":"37","author":"R Haklai","year":"1998","unstructured":"Haklai R, Gana-Weisz G, Elad G, Paz A, Marciano D, Egozi Y, Ben Baruch G, Kloog Y (1998) Dislodgment and accelerated degradation of Ras. Biochemistry 37:1306\u201314","journal-title":"Biochemistry"},{"key":"451_CR20","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","volume":"18","author":"B Weisz","year":"1999","unstructured":"Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579\u201388","journal-title":"Oncogene"},{"key":"451_CR21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1523-1747.2003.12009.x","volume":"120","author":"J Halaschek-Wiener","year":"2003","unstructured":"Halaschek-Wiener J, Kloog Y, Wacheck V, Jansen B (2003) Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol 120:109\u201315","journal-title":"J Invest Dermatol"},{"key":"451_CR22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.999.65.3","volume":"65","author":"R Blum","year":"2005","unstructured":"Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y (2005) Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 65:999\u20131006","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"451_CR23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1525-1438.2006.00508.x","volume":"16","author":"ME Beiner","year":"2006","unstructured":"Beiner ME, Niv H, Haklai R, Elad-Sfadia G, Kloog Y, Ben-Baruch G (2006) Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. Int J Gynecol Cancer 16(Suppl 1):200\u20136","journal-title":"Int J Gynecol Cancer"},{"key":"451_CR24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF03402049","volume":"6","author":"J Halaschek-Wiener","year":"2000","unstructured":"Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, Jansen B (2000) A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 6:693\u2013704","journal-title":"Mol Med"},{"key":"451_CR25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bcp.2006.05.007","volume":"72","author":"S Erlich","year":"2006","unstructured":"Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R (2006) Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 72:427\u201336","journal-title":"Biochem Pharmacol"},{"key":"451_CR26","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-06-0792","volume":"12","author":"B Barkan","year":"2006","unstructured":"Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y (2006) The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 12:5533\u201342","journal-title":"Clin Cancer Res"},{"key":"451_CR27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s001099900052","volume":"77","author":"B Jansen","year":"1999","unstructured":"Jansen B, Heere-Ress E, Schlagbauer-Wadl H, Halaschek-Wiener J, Waltering S, Moll I, Pehamberger H, Marciano D, Kloog Y, Wolff K (1999) Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med 77:792\u20137","journal-title":"J Mol Med"},{"key":"451_CR28","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","volume":"18","author":"B Weisz","year":"1999","unstructured":"Weisz B, Giehl K, Gana-Weisz M, Egozi, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579\u201388","journal-title":"Oncogene"},{"key":"451_CR29","first-page":"555","volume":"8","author":"M Gana-Weisz","year":"2002","unstructured":"Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y (2002) The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8:555\u201365","journal-title":"Clin Cancer Res"},{"key":"451_CR30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.onc.1201005","volume":"14","author":"J Rooij de","year":"1997","unstructured":"de Rooij J, Bos JL (1997) Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14:623\u20135","journal-title":"Oncogene"},{"key":"451_CR31","doi-asserted-by":"crossref","first-page":"30363","DOI":"10.1074\/jbc.M003193200","volume":"275","author":"M Fridman","year":"2000","unstructured":"Fridman M, Maruta H, Gonez J, Walker F, Treutlein H, Zeng J, Burgess A (2000) Point mutants of c-raf-1 RBD with elevated binding to v-Ha-Ras. J Biol Chem 275:30363\u201371","journal-title":"J Biol Chem"},{"key":"451_CR32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10637-005-2908-y","volume":"23","author":"JS Macdonald","year":"2005","unstructured":"Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JLr, Giguere JK, Abbruzzese JL (2005) A phase II study of farnesyltransferase inhibitor R115777 in pancreatic cancer: a southwest oncology group (SWOG9924) study. Invest new drugs 23:485\u201387","journal-title":"Invest new drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0451-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0451-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0451-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T07:18:46Z","timestamp":1707722326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0451-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,10,2]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0451-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,20]]}}}